C
0.710
0.16 (29.07%)
| Previous Close | 0.550 |
| Open | 0.630 |
| Volume | 227,553 |
| Avg. Volume (3M) | 21,140 |
| Market Cap | 39,224,816 |
| Price / Earnings (Forward) | 0.770 |
| Price / Sales | 1.56 |
| Price / Book | 0.340 |
| 52 Weeks Range | |
| Earnings Date | 31 Mar 2025 |
| Profit Margin | -88.66% |
| Operating Margin (TTM) | 24.64% |
| Diluted EPS (TTM) | -0.390 |
| Total Debt/Equity (MRQ) | 0.29% |
| Current Ratio (MRQ) | 12.04 |
| Operating Cash Flow (TTM) | -24.75 M |
| Levered Free Cash Flow (TTM) | -17.08 M |
| Return on Assets (TTM) | -12.13% |
| Return on Equity (TTM) | -17.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Connect Biopharma Holdings Limi | Mixed | Mixed |
AIStockmoo Score
-0.7
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.67 |
|
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 41.16% |
| % Held by Institutions | 44.85% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bml Capital Management, Llc | 31 Dec 2024 | 2,093,232 |
| Choreo, Llc | 31 Dec 2024 | 160,867 |
| Callan Capital, Llc | 31 Dec 2024 | 80,000 |
| Geowealth Management, Llc | 31 Dec 2024 | 10,942 |
| 52 Weeks Range | ||
| Median | 8.00 (1,026.92%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Apr 2025 | 8.00 (1,026.92%) | Buy | 0.710 |
| 31 Mar 2025 | 8.00 (1,026.92%) | Buy | 0.550 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Apr 2025 | Announcement | Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart |
| 31 Mar 2025 | Announcement | Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update |
| 31 Mar 2025 | Announcement | Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma |
| 28 Mar 2025 | Announcement | Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement |
| 03 Mar 2025 | Announcement | Connect Biopharma to Present at Two Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |